A study demonstrated that viral immune evasion enabled breakthrough infections of COVID-19 in patients with lung cancer, highlighting the importance of effective monitoring mechanisms, such as anti-N serology, to track infection rates in specific vulnerable populations.
As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...
